The BBS and EFSPI planned to hold a one day HTA seminar on June 30 at Novartis, but due to the current COVID-19 situation, the organizers have decided to hold it this year as a shortened 2-hour webinar on the same date which is free to attend.

Flyer and full details on how to register

Disclaimer: All comments which were made during the Webinar are from the speakers themselves, and do not necessarily represent the position of the companies and organizations which they represent.

Link to panel discussion recording

Chrissie Fletcher, GSK UK Celebrating 10 Years HTA SIG

Christoph Schürmann, IQWiG, Germany Health-related quality of life endpoints in benefit assessments: Demands and challenges as seen by IQWiG in Germany

Lara Wolfson, Merck USA Issues related to transparency with HTA dossiers

Mark Nuijten, A2M and Univ. of Maastricht, NL & ITU, Turkey An innovative pricing model to assess the price of expensive drugs with an orphan indication

Fred Sorenson, Xcenda, member of BBS board Introduction to moderated panel discussion

Sorry, the comment form is closed at this time.